Candriam SCA’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $150M | Sell |
1,191,380
-478,908
| -29% | -$63.1M | 0.68% | 26 |
|
|
2026
Q1 | $233M | Sell |
1,670,288
-161,897
| -9% | -$22.7M | 1.21% | 10 |
|
|
2025
Q4 | $225M | Buy |
1,832,185
+211,788
| +13% | +$25.7M | 1.12% | 12 |
|
|
2025
Q3 | $180M | Buy |
1,620,397
+110,559
| +7% | +$12.6M | 0.94% | 16 |
|
|
2025
Q2 | $167M | Sell |
1,509,838
-64,606
| -4% | -$6.88M | 0.97% | 17 |
|
|
2025
Q1 | $176M | Sell |
1,574,444
-148,872
| -9% | -$15.4M | 1.1% | 17 |
|
|
2024
Q4 | $159M | Sell |
1,723,316
-364,971
| -17% | -$32.9M | 0.92% | 22 |
|
|
2024
Q3 | $175M | Buy |
2,088,287
+68,367
| +3% | +$5.22M | 1.01% | 17 |
|
|
2024
Q2 | $139M | Sell |
2,019,920
-265,209
| -12% | -$17.7M | 0.84% | 20 |
|
|
2024
Q1 | $167M | Buy |
2,285,129
+44,892
| +2% | +$3.45M | 1.07% | 16 |
|
|
2023
Q4 | $181M | Buy |
2,240,237
+732,381
| +49% | +$57M | 1.25% | 12 |
|
|
2023
Q3 | $113M | Sell |
1,507,856
-173,939
| -10% | -$13.4M | 0.8% | 20 |
|
|
2023
Q2 | $130M | Buy |
1,681,795
+9,827
| +0.6% | +$784K | 0.94% | 17 |
|
|
2023
Q1 | $128M | Buy |
1,671,968
+37,461
| +2% | +$3.1M | 0.89% | 16 |
|
|
2022
Q4 | $140M | Sell |
1,634,507
-376,397
| -19% | -$29.8M | 0.95% | 13 |
|
|
2022
Q3 | $124M | Sell |
2,010,904
-19,355
| -1% | -$1.22M | 0.87% | 17 |
|
|
2022
Q2 | $125M | Buy |
2,030,259
+281,973
| +16% | +$17.5M | 1.03% | 14 |
|
|
2022
Q1 | $104M | Buy |
1,748,286
+161,573
| +10% | +$10.3M | 0.71% | 26 |
|
|
2021
Q4 | $115M | Buy |
1,586,713
+29,102
| +2% | +$2M | 0.74% | 28 |
|
|
2021
Q3 | $109M | Sell |
1,557,611
-34,495
| -2% | -$2.42M | 0.74% | 22 |
|
|
2021
Q2 | $110M | Sell |
1,592,106
-612,830
| -28% | -$40.9M | 0.75% | 21 |
|
|
2021
Q1 | $123M | Sell |
2,204,936
-4
| -0% | -$258 | 1.03% | 12 |
|
|
2020
Q4 | $128M | Buy |
2,204,940
+279,150
| +14% | +$16.8M | 1.02% | 12 |
|
|
2020
Q3 | $122M | Buy |
1,925,790
+235,765
| +14% | +$16.3M | 1.14% | 14 |
|
|
2020
Q2 | $130M | Sell |
1,690,025
-566,972
| -25% | -$43.5M | 1.37% | 10 |
|
|
2020
Q1 | $143M | Buy |
2,256,997
+35
| +0% | +$2.42K | 1.59% | 10 |
|
|
2019
Q4 | $147M | Buy |
2,256,962
+10,067
| +0.4% | +$656K | 1.57% | 10 |
|
|
2019
Q3 | $142M | Buy |
2,246,895
+270,870
| +14% | +$17.7M | 1.89% | 6 |
|
|
2019
Q2 | $134M | Sell |
1,976,025
-23,239
| -1% | -$1.53M | 1.67% | 9 |
|
|
2019
Q1 | $131M | Buy |
1,999,264
+425,351
| +27% | +$28.3M | 1.68% | 8 |
|
|
2018
Q4 | $98.4M | Buy |
1,573,913
+234,620
| +18% | +$16.4M | 1.51% | 10 |
|
|
2018
Q3 | $103M | Buy |
1,339,293
+437,628
| +49% | +$33.1M | 1.37% | 9 |
|
|
2018
Q2 | $63.9M | Buy |
901,665
+136,064
| +18% | +$9.61M | 1.01% | 12 |
|
|
2018
Q1 | $57.7M | Sell |
765,601
-21,804
| -3% | -$1.73M | 0.98% | 11 |
|
|
2017
Q4 | $56.4M | Sell |
787,405
-348,796
| -31% | -$26.5M | 0.98% | 12 |
|
|
2017
Q3 | $92.1M | Sell |
1,136,201
-289,860
| -20% | -$22.2M | 1.61% | 4 |
|
|
2017
Q2 | $101M | Sell |
1,426,061
-92,507
| -6% | -$6.16M | 1.9% | 4 |
|
|
2017
Q1 | $103M | Buy |
1,518,568
+580,801
| +62% | +$40.8M | 2% | 3 |
|
|
2016
Q4 | $67.2M | Buy |
937,767
+95,723
| +11% | +$7.11M | 1.54% | 6 |
|
|
2016
Q3 | $66.6M | Sell |
842,044
-72,140
| -8% | -$5.86M | 1.6% | 7 |
|
|
2016
Q2 | $76.3M | Sell |
914,184
-272,601
| -23% | -$24.2M | 1.98% | 3 |
|
|
2016
Q1 | $108M | Buy |
1,186,785
+23,664
| +2% | +$2.13M | 2.71% | 2 |
|
|
2015
Q4 | $118M | Buy |
1,163,121
+1,331
| +0.1% | +$138K | 3.15% | 2 |
|
|
2015
Q3 | $114M | Buy |
1,161,790
+82,817
| +8% | +$9.2M | 2.8% | 1 |
|
|
2015
Q2 | $126M | Buy |
1,078,973
+126,083
| +13% | +$13.8M | 2.63% | 2 |
|
|
2015
Q1 | $93.5M | Buy |
952,890
+64,765
| +7% | +$6.58M | 1.88% | 3 |
|
|
2014
Q4 | $83.7M | Buy |
+888,125
| New | +$91.9M | 1.75% | 2 |
|
Other funds holding GILD
Candriam SCA's GILD Position: Q2 2026 in Review
Candriam SCA reduced its Gilead Sciences (GILD) stake by 29% in Q2 2026, selling an estimated $63.1M and leaving 1,191,380 shares worth $150M. The position accounts for 0.68% of the portfolio, ranked #26.
Candriam SCA first reported a position in GILD in Q4 2014 and has held it in 47 quarters since. The position peaked at $233M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Candriam SCA held 1,191,380 shares of Gilead Sciences worth $150M as of Q2 2026.
- Candriam SCA sold 478,908 Gilead Sciences shares in Q2 2026, an estimated $63.1M.
- Gilead Sciences made up 0.68% of Candriam SCA's portfolio in Q2 2026, its #26 holding.
- Candriam SCA first reported a position in Gilead Sciences in Q4 2014 and has held it in 47 quarters since.
- Candriam SCA's Gilead Sciences position peaked at $233M in Q1 2026.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.